Batu Biologics Recruits Diagnostics Expert to Oversee Precision-Medicine Company Arm|
Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced the appointment of Vijay Mahant, PhD, to its Scientific Advisory Board. [Batu Biologics (Business Wire)] Press Release
Chi-Med Initiates Sulfatinib Phase II Clinical Trial in Thyroid Cancer
Hutchison China MediTech Limited announced that Hutchison MediPharma Limited has initiated an open-label Phase II clinical trial to evaluate the efficacy and safety of sulfatinib in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer or medullary thyroid cancer in China [Hutchison China MediTech Limite] Press Release
Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan
Exelixis, Inc. and Ipsen jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib, Exelixis’ lead oncology drug. Under the agreement, Ipsen will have exclusive commercialization rights for current and potential future cabozantinib indications outside of the United States, Canada and Japan. [Exelixis, Inc.] Press Release
From our sponsor:
Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.